Informazioni
Non ci sono recensioni
Is IgA Nephropathy a Single Disease?
Pages 3-17
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Pathogenesis and Treatment in IgA Nephropathy
An International Comparison
Tomino
Editore
Springer
Anno
2016
Pagine
342
ISBN
9784431555872
140,00 €
This book discusses the latest findings on the pathogenesis and treatment of IgA nephropathy. It particularly focuses on recently recognized initiation and progression factors and the varying treatment strategies in different regions, such as Asia, Europe, and the United States. More than 40 years have passed since Dr. Jean Berger first described primary IgA nephropathy (“Nephropathy with mesangial IgA-IgG deposits”) as a new disease entity.
Immunohistopathologically, IgA nephropathy is characterized by the granular deposition of IgA (IgA1) and C3 in the glomerular mesangial areas with mesangial cell proliferation and the expansion of mesangial matrices. It is clear that IgA nephropathy is one of the most common types of chronic glomerulonephritis in the world. This disease may lead to end-stage kidney disease, with its enormous economic impact on healthcare everywhere. Efforts by many investigators around the world have gradually clarified various aspects of the pathogenesis and treatment of IgA nephropathy. However, there are many controversial strategies for the treatment of patients with IgA nephropathy throughout the world, as there are several limitations for treatment in each country. This volume provides nephrologists everywhere with an overview and comparison of both global and regional findings in basic and clinical fields in IgA nephropathy. It covers genetic variation, aberrant IgA1 production, and classification etiology, guidelines, and treatment goals, with all chapters written by top international researchers.
-
-
Advances in Genetics of Immunoglobulin A Nephropathy
Pages 19-42
-
Is IgA Nephropathy (IgAN) a Familial or Sporadic Disease?
Pages 43-51
-
Heterogeneity of Aberrant
Pages 53-68
-
Differences of Histological Classification Between the Japanese Histological Grade Classification and the Oxford Classification
Pages 69-87
-
Podocyte Injury and Significance of Urinary Podocalyxin and Megalin
Pages 89-96
-
Complement Activation
Pages 97-114
-
How Different Are the Current Understandings of Treatments for IgA Nephropathy?
Pages 117-125
-
Prognostic Indicators and Treatment of IgA Nephropathy in China
Pages 127-139
-
The Differences in Etiology and Treatment of IgA Nephropathy in Korea
Pages 141-166
-
Differences in Etiology and Treatment in Japan
Pages 167-207
-
IgA Nephropathy from the VALIGA European Study: Differences in Treatment Approaches Within Europe
Pages 209-220
-
Differences in Etiology and Treatment in Scandinavian Countries
Pages 221-240
-
The Implication of the KDIGO Clinical Practice Guidelines on Management of IgA Nephropathy
Pages 241-249
-
Japanese Clinical Practice Guidelines for IgA Nephropathy: Difference from KDIGO Guidelines
Pages 251-262
-
Limitations of RAS Blockade in IgA Nephropathy
Pages 263-301
-
What Is the Goal for Proteinuria in IgA Nephropathy?
Pages 303-309
-
Beyond the Differences in Tonsillectomy in IgA Nephropathy: From Rationale To Indications in Patients
Pages 311-319
-
Is Tonsillectomy a Possible Treatment for IgA Nephropathy from Randomized Controlled Trial (RCT)?
Pages 321-330
-
Validity of the Japanese Clinical Grade Criteria: Results from the Nationwide Retrospective Cohort Study in IgA Nephropathy
Pages 331-338
